p53-derived peptide that selectively inserts into cancer cell membranes (which overexpress MDM-2) causing necrosis without affecting normal cells.
For athletes, the primary value of PNC-27 lies in its ability to selective cancer cell targeting without harm to normal cells.. This mechanism is particularly relevant during high-volume training phases when tissue repair demand exceeds the body's natural recovery capacity.
Variable — onset typically within 2–8 weeks depending on protocol and individual response.
Individual response varies based on injury severity, training load, and baseline health markers.
Very limited human data. Research compound only. Not a cancer treatment.
Always verify current WADA status with your sport's governing body before use in competition.
https://pubmed.ncbi.nlm.nih.gov/18239596/
Start a PNC-27 Protocol
Hatter Labs provides physician-supervised performance protocols with GMP-certified PNC-27 and comprehensive biomarker monitoring.
Get ProtocolCompare & Stack
Start Your Performance Protocol for PNC-27
Hatter Labs provides physician-supervised performance protocols with GMP-certified compounds, biomarker testing, and personalized programs designed around your training goals.
HIPAA Compliant · GMP Certified · Physician Supervised